The 2-series of prostaglandin E (PGE 2 ) is regarded as a pro-cancer prostanoid, whereas the 1-series (PGE 1 ) and the 3-series (PGE 3 ) are considered to act as anti-cancer prostanoids. In the present study, we provide possible reasons why PGE 1 and PGE 3 , but not PGE 2 , exert anti-cancer effects by focusing on each diverged E-type prostanoid (EP)4 receptor-mediated signaling pathway. PGE 1 , PGE 2 and PGE 3 function as full agonists in terms of G as -and G ai -protein-mediated signaling. However, PGE 1 and PGE 3 function as partial agonists of T-cell factor (TCF)/b-catenin (b-cat)-mediated activity, the well-known cancer-related signaling pathway. Furthermore, pretreatment with PGE 1 or PGE 3 almost completely reduces PGE 2 -induced TCF/b-cat activity. These results provide a plausible reason why PGE 1 and PGE 3 function as anti-cancer prostanoids as a result of novel biased activity for EP4 receptors.
EP receptors: EP1, EP2, EP3 and EP4 [4, 5] . Among them, EP4 receptor-mediated signaling has been extensively studied because it is known to be involved in colon cancer malignancy [5] [6] [7] . Thus, COX-2 expression and the de novo synthesis of PGE 2 are induced by the activation of EP4 receptors through G ai -proteinmediated signaling in HCA-7 human colon cancer cells [8, 9] . Another hallmark of colorectal carcinogenesis is an increase in T-cell factor (TCF)/b-catenin (b-cat) transcriptional activity [10] , which is also primarily regulated by the G ai -protein-mediated pathway of EP4 receptors [7, 11] . The EP4 receptor-coupled G ai -protein pathway involves the activation of phosphatidylinositol 3-kinase (PI3K) and the activation of extracellular signal-regulated kinases (ERKs) [12, 13] . PGE 1 , PGE 2 and PGE 3 are synthesized by COX-2 from dihomo-c-linolenic acid, arachidonic acid and eicosapentaenoic acid (EPA), respectively. The metabolism of these fatty acids shares the same enzymes (cytosolic phospholipase A 2 and COX-2) to produce each PGE. The only difference among PGEs is the number of doublebonds in their structures; PGE 1 has one, PGE 2 has two and PGE 3 has three (Fig. 1A) . As noted above, PGE 2 is recognized as a pro-cancer prostanoid [1] [2] [3] , whereas PGE 1 and PGE 3 function as anti-cancer prostanoids [14, 15] . Thus, for example, PGE 1 was reported to inhibit the growth of HeLa human cervical cancer cells [16] and to reduce the growth of and invasion by B16-F10 murine melanoma cells [17] . PGE 3 was previously shown to reduce cellular proliferation in A549 human lung cancer cells [18] and mouse melanoma B16 cells [19] . The anti-cancer cell growth effects of PGE 3 are considered to be mediated in a manner that is independent of the G as -protein/cAMP/protein kinase A (PKA) pathways [15] . Although PGE 1 and PGE 3 exhibit anti-cancer activities, research has focused on nutritional aspects, not the effects of PGE 1 and/or PGE 3 but rather those of dihomo-c-linolenic acid and/or EPA. However, because the structures of PGEs closely resemble each other instead of the fatty acids themselves, their metabolite prostanoids, PGE 1 and PGE 3 , have the ability to activate the same receptors, similar to PGE 2 . We previously reported that endogenous prostanoids may not serve as alternative or spare ligands for noncognitive prostanoid receptors [20, 21] . For example, prostaglandin D 2 (PGD 2 ), PGE 2 and prostaglandin F 2a (PGF 2a ) have been shown to preferentially activate TCF/b-cat-mediated signaling over the G as -protein/ cAMP signaling of D-type prostanoid (DP) receptors and EP2 receptors [20] . Moreover, the susceptibilities of DP receptors to PGE 2 or PGF 2a were~10-fold less than that of EP2 receptors to PGD 2 or PGF 2a ; therefore, EP2 receptors appear to recognize differences in endogenous prostanoids better than DP receptors [20] . Most notably, each endogenous prostanoid exhibits the potential to make same receptor form distinct conformation. Accordingly, endogenous prostanoids should not be recognized as cognate or slow-reacting alternate ligands, and all of them are potential endogenous biased ligands [20] .
At the stage prior to understanding the precise mechanisms of the PGE-induced endogenous/biological functions in physiologically relevant system, we started by focusing on the specific proximal signaling evoked by human EP4 receptor itself, which remains to be verified in terms of biased activities. Thus, by using the HEK-293 cells stably expressing human EP4 receptors, we have evaluated the biased activities of every single PGE-stimulated signaling pathway reported previously. Based on the ability of prostanoids to function as biased ligands, in the present study, we suggest possible reasons why PGE 1 and PGE 3 (but not PGE 2 ) exert anti-cancer effects based on the results of pharmacological and bioinformatics analyses of each diverged EP4 receptor-mediated signaling pathway and also the receptor itself. After termination of the experiments by removal of the medium and placing the plates on ice, the cAMP that formed was measured, as described previously [11, 13, 22] , and then calculated from a standard curve obtained using nonradiolabeled cAMP.
Materials and methods

Western blotting
HEK-EP4 cells were cultured in six-well plates and prior to immunoblot experiments, culture medium was switched to Opti-MEM at 37°C for 16 h containing antibiotics, as stated above. Cells were then treated with either vehicle or indicated concentrations of PGEs for 5 min. Cells were scraped into lysis buffer consisting of 50 mM Tris-HCl (pH 8.0), 5 mM ethylene diamine (pH 8.0), 150 mM NaCl, 0.5% sodium deoxycholate, 1% Nonidet P-40, 10 mM sodium fluoride, 10 mM disodium pyrophosphate, 0.1% SDS, 0.1 mM phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate, 10 lgÁmL À1 leupeptin and 10 lgÁmL À1 aprotinin, as described previously [11, 13, 22] . As reported previously, protein samples of~50 lg were electrophoresed on a 10% SDS/PAGE and transferred to nitrocellulose membranes [11, 13, 22] . After blocking for 1 h with 5% nonfat milk, the membranes were incubated with 1 : 1000 dilutions of either an anti-phospho-ERK1/2 antibody (#43705; Cell Signaling Technology, Danvers, MA, USA) in 5% BSA (Sigma) or a mixture of a 1 : 500 dilution of an anti-ERK1 antibody (sc-93; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and 1 : 20 000 dilution of an anti-ERK2-antobody (sc-154; Santa Cruz Biotechnology) in 5% nonfat milk at 4°C for 16 h. Membranes were washed twice after incubating with the primary antibody, then incubated with a 1 : 4000 dilution of the appropriate secondary antibodies conjugated with horseradish peroxidase, as described previously [9] . To ensure the equal loading of proteins, membranes were stripped and reprobed with the anti-ERK1 and anti-ERK2 antibodies under the conditions described above.
TCF/b-catenin-mediated reporter gene luciferase assay son, WI, USA), as described previously [11] . Cells were treated with either vehicle or the indicated concentrations of PGEs at 37°C for 16 h. In the case of a PGE 1 or PGE 3 competitive assay, PGE 1 or PGE 3 was pretreated for 15 min followed by treatment with PGE 2 for 16 h at 37°C. Cells were lysed and assayed using a Dual luciferase reporter assay system (Promega) in accordance with the manufacturer's instructions with a GL-200 luminometer (Microtech Nichion, Chiba, Japan) or TECAN infinite M200 (TECAN, Mannedorf, Switzerland). Data were normalized by calculating the ratios of firefly luciferase scores with respect to the corresponding renilla luciferase values and corrected for background activity by subtracting FOP flash values from the corresponding TOP flash values, as described previously [11] .
Whole cell radioligand binding assay HEK-EP4 cells were cultured in 10-cm dishes. Prior to the experiments, cell medium was switched to Opti-MEM containing antibiotics, as stated above, at 37°C for 16 h. Cells were trypsinized and re-suspended as 10 5 cells per sample in 100 lL of ice-cold 10 mM MES (pH 6.0; Sigma) buffer containing 0.4 mM ethylene diamine tetraacetic acid and 10 mM MnCl 2 (Sigma). As described previously [11] , 2.5 nM [ 3 H]PGE 2 (GE Healthcare, Waukesha, WI, USA) was used for the binding assay with increased concentrations of PGEs. Samples were incubated at 4°C for 2 h and assays were terminated by filtration through a Whatman GF/C glass filter (Whatman, Maidstone, UK), followed by three to five washes with ice-cold Mes buffer. Radioactivity was measured by liquid scintillation counting, as described previously [11] .
In silico analysis
The construction of the three-dimensional structure of human EP4 receptors and a docking simulation of PGEs to EP4 receptors were performed with MOE, version 2016.08 (CCG Inc., Montreal, Canada) based on the Brookhaven Protein Databank 4GRV.
Statistical analysis
The multiple comparison tests in the analysis of variance comprised Newman-Keuls multiple comparison tests conducted using Prism, version 5 (GraphPad Software, La Jolla, CA, USA).
Results and Discussion
Effects of PGEs on G as -and G ai -mediated signaling by EP4 prostanoid receptors Human EP4 prostanoid receptors have been reported to be coupled not only with G as -proteins, but also with G ai -proteins [5] [6] [7] . To clarify the reasons for functional differences among the series of PGE ligands (PGE 1 , PGE 2 and PGE 3 ), each G as -or G aiprotein-mediated signaling pathway in human EP4 receptors was evaluated using HEK cells stably expressing human EP4 receptors (HEK-EP4 cells) [11, 13, 22] . G as -protein-mediated signaling was assessed using cAMP formation assay, whereas G ai -proteinmediated signaling was evaluated by the phosphorylation of ERKs, as reported previously [13, 22] . As shown in Fig. 1B ,D, all PGEs induced cAMP formation (Fig. 1B) and ERK phosphorylation (Fig. 1D ) to similar maximal levels (i.e. to E max ). However, as shown in Fig. 1C 
Effects of PGEs on TCF/b-catenin-mediated signaling by EP4 prostanoid receptors
We previously reported that EP4 receptors stimulate TCF/b-cat-mediated transcriptional activity mainly (~70%) via the utilization of G ai -protein-mediated PI3K and also via G as -protein-mediated PKA (~20%) [11] . Thus, the effects of PGE 1 PGE 2 and PGE 3 on TCF/b-cat-mediated transcriptional activities were examined in HEK-EP4 cells. As shown in Fig. 2A , PGE 2 stimulated TCF/b-cat-mediated transcriptional activity in a concentration-dependent manner, with maximal activation of more than 400%. PGE 1 and/or PGE 3 also stimulated TCF/b-cat-mediated activity in a concentration-dependent manner; however, maximal activities were~200% for both PGEs. Although the E max values of PGE 1 and PGE 3 were approximately half that of PGE 2 , EC 50 values were similar among PGEs (Fig. 2B) . Thus, PGE 1 and PGE 3 functioned as partial agonists to EP4 receptor-mediated TCF/b-catmediated activity, which differs from the results shown in Fig. 1 , where they are seen to act as full agonists (i.e. similar to PGE 2 , of G as -protein-mediated cAMP formation as well as G ai -protein-mediated phosphorylation of ERKs). (Fig. 2D) . These results clearly showed that the binding affinity of each PGE to EP4 receptors is identical. As shown in Fig. 1B ,C, PGE 1 acted in a similar manner to PGE 2 (i.e. as a full agonist) in terms of its ability to induce cAMP. However, regarding ERK phosphorylation, its efficacy was similar to PGE 2 (i.e. as a full agonist), whereas its potency was weaker than that of PGE 2 ( Fig. 1D,E) . Regarding TCF/b-cat-mediated transcriptional activity, the efficacy of PGE 1 was lower, whereas its potency was similar to PGE 2 ; therefore, it functioned as a partial agonist of EP4 receptors ( Fig. 2A) . Because the affinity of PGE 1 to EP4 receptors is equal to that of PGE 2 , PGE 1 appears to be insensitive to the activation of TCF/b-cat signaling (i.e. it will be a biased full agonist for G as -and G ai -mediated signaling with weaker potency to the G ai -pathway than PGE 2 ). By contrast, PGE 3 acted as a full agonist, although with lower potencies for G asand G ai -mediated signaling pathways (cAMP and the phosphorylation of ERKs, respectively), and as a partial agonist of TCF/b-cat-mediated signaling (similar to PGE 1 ) for EP4 receptors relative to PGE 2 . Thus, PGE 3 will be a biased full agonist of G as -and G ai -mediated signaling pathways with weak potency and is insensitive to the activation of TCF/b-catmediated signaling by EP4 receptors.
PGEs may bind differently and form distinct hydrogen bonds with EP4 receptors
The number of double-bonds in the side chains of these three PGEs differs (Fig. 1A) . Therefore, in silico simulations were performed to examine the interactions of these three PGEs with EP4 receptors. Figure 3 shows the predicted binding pocket for PGEs on EP4 receptors. The interactions between each PGE and EP4 receptors were simulated and are shown in Fig. 3C -H. All PGEs essentially have the same important functional groups, which form hydrogen bonds with EP4 receptors, namely, carbonyl functional groups at positions 1 and 9 and a hydroxyl group at position 15. However, although these three functional groups are key groups, each PGE forms slightly different bonds, particularly at positions 9 and 15. Thus, PGE 1 and PGE 3 form two hydrogen bonds at the carbonyl groups in cyclopenta ring position 9 to R291 in transmembrane (TM) 6 domain, whereas only a single bond is formed with the hydroxyl group in side chain position 15 with S307 in the TM 7 domain of the receptors. PGE 2 forms a single hydrogen bond at the carbonyl groups in position 9 to R291 in the TM 6 domain, whereas two bonds are formed with the hydroxyl group in side chain position 15 with S307 in the TM7 domain of the receptors. Thus, the biased activities of PGE 1 and PGE 3 for TCF/b-cat-mediated signaling appear to be related to the numbers and patterns of bonding formation between PGEs and EP4 receptors, which may not be able to transform the receptor conformation fully to activate signaling evoked by PGE 2 .
Effects of PGE 1 and PGE 3 on PGE 2 -stimulated EP4 receptor activation
As noted in the Introduction, in contrast to the procancer prostanoid PGE 2 , PGE 1 and PGE 3 function as anti-cancer prostanoids. We found that PGE 1 and PGE 3 both induced TCF/b-cat-mediated transcriptional activity, a known marker for early colorectal cancer, by~50% relative to that induced by PGE 2 ( Fig. 2A) , acting as biased ligands. Thus, the possible suppressive roles of PGE 1 and PGE 3 were examined by estimating PGE 2 -induced TCF/b-cat-mediated transcriptional activity. As shown in Fig. 4A , pretreatment with PGE 1 or PGE 3 almost completely reduced PGE 2 -induced TCF/b-cat-mediated transcriptional activity to the level of PGE 1 or PGE 3 alone. Similar tendencies were obtained when using human HCA-7 colon cancer cells treated with PGEs (data not shown). However, because HCA-7 cells have been shown to express not only EP4 receptors, but also EP2 and EP3 receptors [23, 24] , it remains to be confirmed whether the anticancer effects of PGE 1 and PGE 3 are mediated by EP4 receptors and/or by biased activities. On the other hand, as shown in Fig. 4B , in the case of PGE-induced cAMP formation, all PGEs tested induced similar levels of cAMP formation, although neither PGE 1 , nor PGE 3 pretreatment altered PGE 2 -induced cAMP formation. Therefore, PGE 1 and PGE 3 showed negative biases to TCF/b-cat-mediated signaling but not to G as -protein-mediated cAMP signaling. As noted above, we previously reported that EP4 receptors stimulate TCF/b-cat-mediated transcriptional activity mainly (~70%) via the utilization of G ai -proteinmediated PI3K and also via G as -protein-mediated PKA (~20%) [11] . Thus, as shown in Fig. 1D , the 10 nM PGE 2 -stimulated phosphorylation of ERKs (G ai -protein-mediated pathway) was significantly greater compared to that achieved with 10 nM PGE 1 or 10 nM PGE 3 . Additionally, as shown in Fig. 1B, 10 nM PGE 2 -stimulated cAMP formation (G as -proteinmediated pathway) was similar to that evoked by 10 nM PGE 1 or 10 nM PGE 3 . Therefore, the inhibitory effects of PGE 1 and PGE 3 on PGE 2 -stimulated TCF/ b-cat-mediated transcriptional activity may be a result of insufficient activation of the G ai -protein-mediated pathways evoked by PGE 1 or PGE 3 . However, the efficacies of cAMP and the phosphorylation of ERKs were not significantly different among the PGEs, whereas the potencies differed. In the case of the efficacies of TCF/b-cat-mediated signaling, they differed among PGEs, whereas their potencies were the same. The affinities of PGEs to EP4 receptors (Fig. 2D) were similar and the EC 50 values of PGEs on TCF/b-cat signaling (Fig. 2B) , at least for PGE 1 and PGE 2 , were similar to that shown in Fig. 1C (G as -protein-mediated pathway), whereas they were lower than that observed for the phosphorylation of ERKs (G ai -proteinmediated pathway), as shown in Fig. 1E . Thus, TCF/ b-cat-mediated signaling may be the third signaling pathway that is independent of G as -or G ai -proteinmediated signaling. Otherwise, the TCF/b-cat signaling pathways originated from the merged signalings of G as -and/or G ai -protein-dependent and independent signaling pathways; these pathways need to be clarified in more detail. Nevertheless, PGE 1 and PGE 3 exhibited the ability to specifically attenuate PGE 2 -induced procancer signaling (i.e. TCF/b-cat-mediated transcriptional activity as biased agonists) without changing other signaling pathways, such as cAMP formation.
Conclusions
In the present study, using HEK-293 cells stably expressing human EP4 receptors, we suggest possible . Data are normalized to each vehicle-treated control as 100% and are the mean AE SEM of at least three independent experiments, each performed in duplicate (A). Data are normalized to cAMP formation obtained following 10 nM PGE 2 stimulation as 100% and are the mean AE SEM of at least three independent experiments, each performed in duplicate (B). †P < 0.05: analysis of variance (for PGE 3 ) significantly different from the corresponding concentrations of PGE 2 . ‡P < 0.05: analysis of variance (for PGE 1 ) significantly different from the corresponding concentrations of PGE 2 . The E max values obtained from each PGE-induced cAMP formation and ERK phosphorylation were not significantly different; therefore, each PGE was a full agonist of EP4 receptors (C). The E max values obtained from each PGE-stimulated TCF/b-cat-mediated luciferase assay for PGE 1 or PGE 3 were lower than that for PGE 2 ; thus, PGE 1 and PGE 3 may be biased agonists (negatively biased to TCFb-cat signaling) (C). Vehi, vehicle; GSK3, glycogen synthase kinase-3.
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reasons why PGE 1 and PGE 3 (but not PGE 2 ) exert anti-cancer effects, functioning as biased ligands. Although, to some extent, the biological relevance of the findings is limited, differences in the proximal signaling evoked by the human EP4 receptor itself with each PGE are indicative of novel regulatory mechanisms that have not been verified yet in terms of biased activities. Note that these biased functional differences among PGEs were determined only because the EP4 receptor expressing HEK cell system is a good model system for exploring relatively pure receptor functions in conjunction with bioinformatics approaches. Clearly, additional studies are needed, especially to confirm the endogenous/biological relevance of PGEs. Nonetheless, these results provide a plausible reason with respect to why PGEs function as either pro-or anti-cancer prostanoids, not as a result of nutritional aspects but because of novel biased activity for EP4 receptors. Thus, the anti-cancer and/or pro-cancer effects are both mediated by the same EP4 prostanoid receptors, although the outputs depend on the biased functions of each endogenous PGE.
